Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression

171Citations
Citations of this article
69Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Despite many refinements in current therapeutic strategies, the overall prognosis for a patient with glioblastoma is dismal. Neural precursor cells (NPCs) are capable of tracking glioma tumors and thus could be used to deliver therapeutic molecules. We have engineered mouse NPCs to deliver a secreted form of tumor necrosis factor-related apoptosis-inducing ligand (S-TRAIL); S-TRAIL is optimized to selectively kill neoplastic cells. Furthermore, we have developed means to simultaneously monitor both the migration of NSCs toward gliomas and the changes in glioma burden in real time. Using a highly malignant human glioma model expressing Renilla luciferase (Rluc), intracranially implanted NPC-FL-sTRAIL expressing both firefly luciferase (Flue) and S-TRAIL was shown to migrate into the tumors and have profound antitumor effects. These studies demonstrate the potential of NPCs as therapeutically effective delivery vehicles for the treatment of gliomas and also provide important tools to evaluate the migration of NPCs and changes in glioma burden in vivo.

Cite

CITATION STYLE

APA

Shah, K., Bureau, E., Kim, D. E., Yang, K., Tang, Y., Weissleder, R., & Breakefield, X. O. (2005). Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology, 57(1), 34–41. https://doi.org/10.1002/ana.20306

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free